Molecular Partners : MP Corporate Presentation

Custom Built Biology for Patients

Corporate Deck

September 2021

Molecular Partners AG, Switzerland

(SIX: MOLN, NASDAQ: MOLN)

1

Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates, including timing for the potential submission of emergency use authorization for ensovibep, expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials, the potential therapeutic and clinical benefits of Molecular Partners' product candidates, the selection and

development of future antiviral or other programs, and Molecular Partners' expected expenses and cash utilization for 2021 and that its current cash resources will be sufficient to fund its

operations and capital expenditure requirements into H2 2023. These statements may be identified by words such as "anticipate", "believe", "could", "expect", "intend", "may", "plan", "potential", "will", "would" and similar expressions, although not all forward-looking statements may contain these identifying words, and are based on Molecular Partners AG's current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from our expectations include our plans to develop and potentially commercialize our product candidates; our reliance on third party partners and collaborators over which we may not always have full control; our ongoing and planned clinical trials and preclinical studies for our product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the extent of clinical trials potentially required for our product candidates; the clinical utility and ability to achieve market acceptance of our product candidates; the potential impact of the COVID19 pandemic on our operations or clinical trials; our plans and development of any new indications for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position; our ability to identify and in-license additional product candidates; the adequacy of our cash resources and our anticipated cash utilization; and other risks and uncertainties that are described in the Risk Factors section of Molecular Partners' Registration Statement on Form F-1 filed with Securities and Exchange Commission (SEC) on June 14, 2021 and other filings Molecular Partners makes with the SEC. These documents are available on the Investors page of Molecular Partners' website at http://www.molecularpartners.com.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

2

Pioneering DARPin® Therapeutics

COVID19 - Ensovibep (Novartis)

• Phase 1 & small trial in patients completed
• 2 pivotal trials ongoing, recruiting well
• • EMPATHY - ambulatory
  • ACTIV-3 - hospitalized
• Activity on all viral variants of concern

Local immune agonists

• AMG 506 / MP0310 - (FAP x 4-1BB, Amgen) weekly dosing; on track to initial read-out in H2/2021
• MP0317 - (FAP x CD40) on track to FIH in H2/2021

AML (CD33+CD70+CD123 x CD3)

• Triple-TAA-targetingTCE on track for candidate selection in H2/2021
• First in human 2022

• Financials
• • Listed on NASDAQ
  • Raised CHF 58 million gross proceeds
  • Strong balance sheet, funded into H2 2023
• Infectious disease
• • Announcing new programs at R&D day Dec. 2021
• Abicipar
• • Molecular Partners will regain rights from AbbVie; transition and evaluation of data initiated

3

What are DARPin® Proteins

MONOCLONAL ANTIBODIES

Binding regions / specificities

15 kDa

150 kDa

• High affinity and specificity
• Large size: 150 kDa
• Complex architecture; 4 proteins with 12 domains
• Long half-life
• Mammalian expression
• Good safety & low immunogenic potential

MONO-DARPin PROTEINS

Binding region / specificity

DARPin module

Multi-specific DARPin Product

Candidate

• High affinity and specificity
• Small size: 15 kDa (1/10 of a monoclonal antibody)
• Simple architecture 1 protein with 1 domain
• Tunable half-life
• High-yieldmicrobial expression; High stability
• Good safety & low immunogenic potential

4

Multi-DARPin® Versatility Allows Screening for Function Sweet Spot

# molecules

1012

10s

Super Large Libraries with DARPin Binders to any given target

Simple selection of specific DARPin binders (functional, well behaved, highly potent)

Multi-domain DARPin® space

DARPins

Assembly of up to 6 DARPin® modules:

Fast & high throughput process: 2 weeks

1000s	Screening of multi-domain
DARPin® space for the SOLUTION
2-5	Specific Multi-DARPin® product
candidate with desired function

to Target 1

DARPins to Target 2

DARPins to Target 3

5